GILEAD SCIENCES, INC. — fact timeline

GILEAD SCIENCES, INC. incurred senior notes of $500,000,000 aggregate principal amount of the Company’s 4.250% Senior Notes due 2028, $1,000,000,000 aggregate principa with Computershare Trust Company, National Association, as trustee at 4.250% per annum until May 20, 2028; 4.400% per annum until May 20, 2029; 4.600% maturing May 20, 2028; May 20, 2029; May 20, 2031; May 20, 2034.

“Supplemental Indenture On May 20, 2026, Gilead Sciences, Inc. (the “Company”) and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, as trustee (the “Trustee” and, together with the Company, the “Parties”), entered into an Eleventh Supplemental Indenture (the “Eleventh Supplemental Indenture”) to the Indenture between the Parties, dated as of March 30, 2011 (the “Base Indenture”). The Eleventh Supplemental Indenture relates to the Company’s issuance of (a) $500,000,000 aggregate principal amount of the Company’s 4.250% Senior Notes due 2028 (the “2028 Notes”), (b) $1,000,000,000 aggregate principal amount of the Company’s 4.400% Senior Notes due 2029 (the “2029 Notes”), (c) $1,000,000,000 aggregate principal amount of the Company’s 4.600% Senior Notes due 2031 (the “2031 Notes”) and (d) $500,000,000 aggregate principal amount of the Company’s 4.900% Senior Notes due 2034 (the “2034 Notes” and, together with the 2028 Notes, the 202”

GILEAD SCIENCES, INC. reported first quarter 2026 results: revenue $7.0 billion, EPS $1.61. Guidance raised.

“in 2026, Gilead is well-positioned for sustained growth in the near and long term.” First Quarter 2026 Financial Results • Total first quarter 2026 revenues increased 4% to $7.0 billion compared to the same period in 2025, primarily driven by higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy), and Livdelzi® (seladelpar), partially offset by”

GILEAD SCIENCES, INC. entered into Merger Agreement with Arcellx, Inc. (effective 2026-02-22).

“On February 22, 2026, Gilead Sciences, Inc., a Delaware corporation (“ Parent ” or “ Gilead ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), among Parent, Arcellx, Inc., a Delaware corporation (the “ Company ”), and Ravens Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”).”

GILEAD SCIENCES, INC.: Amended and restated bylaws to revise procedural and disclosure requirements for director nominations and stockholder proposals, reserve white proxy card, update provisions regarding adjournment and stockholder list under DGCL, clarify majority vote provisions, and add emergency condition provisions (effective 2025-07-30).

“On July 30, 2025 , the Board of Directors (the “Board”) of Gilead Sciences, Inc. (the “Company”) approved an amendment and restatement of the Company’s bylaws (the “Amended and Restated Bylaws”), effective as of such date, in order to: • revise the procedural and disclosure requirements for the nomination of directors and the submission of proposals for consideration at meetings of the stockholders under the advance notice provisions (other than proposals to be included in the Company’s proxy statement pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), including, without limitation, by: ◦ clarifying and enhancing the background information and disclosures required by or regarding proposing stockholders, proposed nominees and business, and other control persons or persons known to be acting in concert with a proposing stockholder, including with respect to certain plans or proposals of and any planned solicitation by such persons; ◦ clari”

Diane E. Wilfong was appointed as interim Corporate Controller and Chief Accounting Officer at GILEAD SCIENCES, INC..

“The Company’s Board of Directors has appointed Diane E. Wilfong as the Company’s interim Corporate Controller and Chief Accounting Officer, and designated her as the interim principal accounting officer, effective immediately.”

Sandra Patterson departed as Senior Vice President, Corporate Controller and Chief Accounting Officer at GILEAD SCIENCES, INC..

“Sandra Patterson, the Company’s Senior Vice President, Corporate Controller and Chief Accounting Officer and the Company’s principal accounting officer, has decided to leave the Company.”

Merdad V. Parsey resigned as Chief Medical Officer at GILEAD SCIENCES, INC..

“announced that its Chief Medical Officer, Merdad V. Parsey, M.D., Ph.D., will leave the Company.”

GILEAD SCIENCES, INC.: Adopted amendments to the Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation under Section 102(b)(7) of the DGCL (effective 2024-05-08).

“the Board of Directors (the “Board”) of Gilead Sciences, Inc. (the “Company”) adopted amendments to the Company’s Restated Certificate of Incorporation (the “Amendment”) to reflect new Delaware law provisions regarding officer exculpation under Section 102(b)(7) of the Delaware General Corporation Law (the “DGCL”). On May 8, 2024 , the Company’s stockholders approved the Amendment at the Company’s 2024 annual meeting of stockholders”

GILEAD SCIENCES, INC. shareholders rejected Stockholder proposal requesting that the Board adopt a policy requiring the Company’s named executive officers to retain at least 25% of net-after tax shares of stock acquired through equity pay programs until reaching normal retirement age (at least age 60) at the 2024-05-08 meeting.

“The Company’s stockholders did not approve a stockholder proposal requesting that the Board adopt a policy requiring the Company’s named executive officers to retain at least 25% of net-after tax shares of stock acquired through equity pay programs until reaching normal retirement age (at least age 60). The proposal received the following votes: Votes For 361,356,676 Votes Against 645,764,310 Abstentions 2,044,338 Broker Non-Votes 106,243,270”

GILEAD SCIENCES, INC. shareholders rejected Stockholder proposal requesting that the Board issue a report detailing the risks and costs to the Company caused by opposing or otherwise altering Company policy in response to state policies regulating abortion, and detailing any strategies beyond litigation and legal compliance that the Company m at the 2024-05-08 meeting.

“The Company’s stockholders did not approve a stockholder proposal requesting that the Board issue a report detailing the risks and costs to the Company caused by opposing or otherwise altering Company policy in response to state policies regulating abortion, and detailing any strategies beyond litigation and legal compliance that the Company may deploy to minimize or mitigate these risks. The proposal received the following votes: Votes For 17,930,954 Votes Against 977,168,730 Abstentions 14,065,640 Broker Non-Votes 106,243,270”

GILEAD SCIENCES, INC. shareholders rejected Stockholder proposal requesting that the Board include one member from the Company’s non-management employees at the 2024-05-08 meeting.

“The Company’s stockholders did not approve a stockholder proposal requesting that the Board include one member from the Company’s non-management employees. The proposal received the following votes: Votes For 59,235,065 Votes Against 946,161,838 Abstentions 3,768,421 Broker Non-Votes 106,243,270”

GILEAD SCIENCES, INC. shareholders approved Amendment to the Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation at the 2024-05-08 meeting.

“The Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. The proposal received the following votes: Vote For 905,468,022 Vote Against 101,692,634 Abstentions 2,004,668 Broker Non-Votes 106,243,270”

GILEAD SCIENCES, INC. shareholders approved Advisory approval of compensation of named executive officers as presented in the Proxy Statement at the 2024-05-08 meeting.

“The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s Named Executive Officers as presented in the Proxy Statement. The proposal received the following votes: Votes For 928,702,915 Votes Against 78,647,808 Abstentions 1,814,601 Broker Non-Votes 106,243,270”

GILEAD SCIENCES, INC. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-08 meeting.

“The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The proposal received the following votes: Votes For 1,039,381,050 Votes Against 74,100,517 Abstentions 1,927,027”

GILEAD SCIENCES, INC. shareholders approved Election of nine directors to serve for the next year and until their successors are elected and qualified at the 2024-05-08 meeting.

“The Company’s stockholders elected nine directors to serve for the next year and until their successors are elected and qualified. The votes regarding the election of directors were as follows: Name Votes For Votes Against Abstentions Broker Non-Votes Jacqueline K. Barton, Ph.D. 995,391,975 12,399,781 1,373,568 106,243,270 Jeffrey A. Bluestone, Ph.D. 1,000,314,606 7,419,797 1,430,921 106,243,270 Sandra J. Horning, M.D. 985,486,994 22,304,826 1,373,504 106,243,270 Kelly A. Kramer 980,895,123 26,851,069 1,419,132 106,243,270 Ted W. Love, M.D. 1,002,644,132 5,021,345 1,499,847 106,243,270 Harish Manwani 968,115,418 39,518,665 1,531,241 106,243,270 Daniel P. O’Day 939,111,309 63,134,940 6,919,075 106,243,270 Javier J. Rodriguez 1,000,194,729 7,506,046 1,464,549 106,243,270 Anthony Welters 932,173,164 75,508,127 1,484,033 106,243,270”

GILEAD SCIENCES, INC. reported the quarter ended March 31, 2024 results: revenue $6.7 billion, EPS $(3.34).

“providing updates on this and our broad Oncology portfolio throughout the rest of 2024.” First Quarter 2024 Financial Results • Total first quarter 2024 revenue increased 5% to $6.7 billion, compared to the same period in 2023, primarily due to higher HIV, Oncology and Liver Disease sales. • Diluted (loss) earnings per share (“EPS”) was $(3.34) in the first quarter”